CureVac BV reports Q3 results

Nov. 16, 2022 7:37 AM ETCureVac N.V. (CVAC)By: Deepa Sarvaiya, SA News Editor
  • CureVac BV press release (NASDAQ:CVAC): Q3 Pre-tax loss was €47.7M
  • Revenue of €11.2M (-61.8% Y/Y).
  • Cash and cash equivalents position of €540.9 million as of September 30, 2022; driven mainly by proceeds related to transfer of production capacity to GSK

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.